DE60011617T2 - Zeitgesteuert freisetzende dosierungsformen enthaltend ein kurz wirksames hypnotikum oder ein salz davon - Google Patents

Zeitgesteuert freisetzende dosierungsformen enthaltend ein kurz wirksames hypnotikum oder ein salz davon Download PDF

Info

Publication number
DE60011617T2
DE60011617T2 DE60011617T DE60011617T DE60011617T2 DE 60011617 T2 DE60011617 T2 DE 60011617T2 DE 60011617 T DE60011617 T DE 60011617T DE 60011617 T DE60011617 T DE 60011617T DE 60011617 T2 DE60011617 T2 DE 60011617T2
Authority
DE
Germany
Prior art keywords
release
pharmaceutical preparation
preparation according
delayed
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011617T
Other languages
German (de)
English (en)
Other versions
DE60011617D1 (de
Inventor
Gerard Alaux
Frederic Andre
Jean Ducassou
Gareth Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8242028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60011617(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of DE60011617D1 publication Critical patent/DE60011617D1/de
Publication of DE60011617T2 publication Critical patent/DE60011617T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60011617T 1999-06-28 2000-06-27 Zeitgesteuert freisetzende dosierungsformen enthaltend ein kurz wirksames hypnotikum oder ein salz davon Expired - Lifetime DE60011617T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99401605 1999-06-28
EP99401605A EP1064937A1 (en) 1999-06-28 1999-06-28 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
PCT/EP2000/006792 WO2001000181A2 (en) 1999-06-28 2000-06-27 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof

Publications (2)

Publication Number Publication Date
DE60011617D1 DE60011617D1 (de) 2004-07-22
DE60011617T2 true DE60011617T2 (de) 2005-06-09

Family

ID=8242028

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60011617T Expired - Lifetime DE60011617T2 (de) 1999-06-28 2000-06-27 Zeitgesteuert freisetzende dosierungsformen enthaltend ein kurz wirksames hypnotikum oder ein salz davon

Country Status (28)

Country Link
EP (2) EP1064937A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003503340A (cg-RX-API-DMAC7.html)
KR (1) KR20020015064A (cg-RX-API-DMAC7.html)
CN (1) CN100415216C (cg-RX-API-DMAC7.html)
AR (1) AR024491A1 (cg-RX-API-DMAC7.html)
AT (1) ATE269062T1 (cg-RX-API-DMAC7.html)
AU (1) AU782162B2 (cg-RX-API-DMAC7.html)
BR (1) BR0011994A (cg-RX-API-DMAC7.html)
CA (1) CA2370556C (cg-RX-API-DMAC7.html)
CO (1) CO5190680A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20014640A3 (cg-RX-API-DMAC7.html)
DE (1) DE60011617T2 (cg-RX-API-DMAC7.html)
DK (1) DK1194132T3 (cg-RX-API-DMAC7.html)
ES (1) ES2222223T3 (cg-RX-API-DMAC7.html)
HK (1) HK1043057B (cg-RX-API-DMAC7.html)
HU (1) HU227810B1 (cg-RX-API-DMAC7.html)
IL (1) IL146928A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01013212A (cg-RX-API-DMAC7.html)
NO (1) NO20016283L (cg-RX-API-DMAC7.html)
NZ (1) NZ515997A (cg-RX-API-DMAC7.html)
PL (1) PL201777B1 (cg-RX-API-DMAC7.html)
PT (1) PT1194132E (cg-RX-API-DMAC7.html)
SI (1) SI1194132T1 (cg-RX-API-DMAC7.html)
SK (1) SK285347B6 (cg-RX-API-DMAC7.html)
TR (1) TR200103594T2 (cg-RX-API-DMAC7.html)
TW (1) TWI285118B (cg-RX-API-DMAC7.html)
WO (1) WO2001000181A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200110005B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
PT1206248E (pt) * 1999-08-26 2003-11-28 Neurocrine Biosciences Inc Composicoes sedativo-hipnoticas de libertacao controlada e metodos relacionados com os mesmos
US7811557B1 (en) * 2000-10-27 2010-10-12 Viacell, Inc. Methods for improving central nervous system functioning
CA2447008A1 (en) * 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DK1404331T3 (da) 2001-07-06 2008-01-28 Penwest Pharmaceuticals Co Sustained release-formuleringer af oxymorphon
KR20030034171A (ko) 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
CA2469673A1 (en) * 2001-12-19 2003-06-26 Sanwa Kagaku Kenkyusho Co., Ltd. Controlled release molded product
EP1941878A1 (en) * 2002-01-10 2008-07-09 Biovail Laboratories International Srl Sedative non-benzodiazepine formulations
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
WO2003059349A1 (en) * 2002-01-10 2003-07-24 Biovail Laboratories Inc. Sedative non-benzodiazepine formulations
EP1556024A4 (en) * 2002-10-25 2007-01-17 Collegium Pharmaceutical Inc INTERMITTENT LIBERATION COMPOSITIONS OF MILNACIPRANE
JP4681843B2 (ja) * 2004-09-30 2011-05-11 日本臓器製薬株式会社 固形医薬製剤
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
FR2887455B1 (fr) * 2005-06-28 2007-08-10 Sanofi Aventis Sa Formulation a liberation prolongee de principes actifs de medicaments
WO2007065559A1 (en) * 2005-11-18 2007-06-14 Synthon B.V. Zolpidem tablets
AR056633A1 (es) * 2005-12-07 2007-10-17 Gador Sa Composiciones farmaceuticas de agentes hipnoticos de accion corta en forma de liberacion modificada y los procedimientos para preparar dichas formulaciones
US8309104B2 (en) * 2006-03-02 2012-11-13 Watson Pharmaceuticals, Inc. Oral controlled release formulation for sedative and hypnotic agents
KR20070091960A (ko) * 2006-03-08 2007-09-12 주식회사종근당 졸피뎀 또는 그의 염을 포함하는 안전한 제어방출형 제제조성물
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
AU2007242077B2 (en) * 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
JP5275560B2 (ja) * 2006-10-24 2013-08-28 小林化工株式会社 酒石酸ゾルピデム含有素錠の製造方法
EP1938805A1 (en) * 2006-12-22 2008-07-02 LEK Pharmaceuticals D.D. Monolithic sustained release zolpidem tablets
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
WO2009021127A2 (en) * 2007-08-07 2009-02-12 Neurogen Corporation Controlled released compositions
DK2276473T3 (en) 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
US20100068266A1 (en) 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo-modifiable multiple-release state final dosage form
WO2010064139A2 (en) 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
RU2384336C1 (ru) * 2009-04-22 2010-03-20 Маргарита Алексеевна Морозова Фармацевтический состав для коррекции психосоматических проявлений
CA2767238A1 (en) * 2009-07-07 2011-01-13 Sunovion Pharmaceuticals Inc. Formulations of 6- (5-chloro-2-pyridyl) - 5- [ (4-methyl-1-piperazinyl) carbonyloxy] - 7-0x0-6, 7- dihydro-5h-phyrrolo [3, 4-b] pyrazine
FR2949062B1 (fr) * 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
FR2968992B1 (fr) * 2010-12-16 2013-02-08 Sanofi Aventis Comprime pharmaceutique orodispersible a base de zolpidem
TWI505841B (zh) * 2011-09-29 2015-11-01 Taiwan Biotech Co Ltd 治療睡眠障礙之控釋調配物
MY177906A (en) * 2014-02-06 2020-09-25 Sequential Medicine Ltd Composition and method for aiding sleep
RU2659200C1 (ru) * 2017-07-24 2018-06-28 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтический состав, содержащий алимемазина тартрат

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
GB2185887B (en) * 1987-02-18 1989-12-06 Farmitalia Carlo Erba Ltd Temazepam composition
ATE107854T1 (de) * 1988-09-30 1994-07-15 Rhone Poulenc Rorer Ltd Pharmazeutisches granulat.
FR2656303B1 (fr) * 1989-12-26 1994-06-10 Parke Davis Solution buvable d'un derive des benzodiazepines et son application pharmacologique.
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
IT1276689B1 (it) * 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
FR2742660B1 (fr) * 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
BR9802915A (pt) * 1997-09-12 2000-01-11 Oscar Gold Procedimento para formar composições farmaceuticas em pilulas ou granulos substancialmente esfericos, de ação controlada e continuada, contendo como agente ativo o (7-bromo-1,3-diidro-5-(2-piridninilo)-2h-1,4-benzodiazep ina-2(1h)-um)
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof

Also Published As

Publication number Publication date
EP1194132A2 (en) 2002-04-10
TR200103594T2 (tr) 2002-06-21
CZ20014640A3 (cs) 2002-03-13
HUP0201907A3 (en) 2004-05-28
HU227810B1 (en) 2012-03-28
PL357348A1 (en) 2004-07-26
JP2003503340A (ja) 2003-01-28
DK1194132T3 (da) 2004-10-11
BR0011994A (pt) 2002-03-05
CN1358087A (zh) 2002-07-10
WO2001000181A2 (en) 2001-01-04
CA2370556A1 (en) 2001-01-04
SI1194132T1 (en) 2004-10-31
KR20020015064A (ko) 2002-02-27
IL146928A0 (en) 2002-08-14
AU782162B2 (en) 2005-07-07
HUP0201907A2 (hu) 2002-12-28
CN100415216C (zh) 2008-09-03
NO20016283L (no) 2002-02-27
NZ515997A (en) 2004-03-26
AR024491A1 (es) 2002-10-02
WO2001000181A3 (en) 2001-03-01
ATE269062T1 (de) 2004-07-15
ZA200110005B (en) 2003-02-26
ES2222223T3 (es) 2005-02-01
AU6694400A (en) 2001-01-31
HK1043057B (en) 2005-02-25
EP1064937A1 (en) 2001-01-03
PT1194132E (pt) 2004-10-29
MXPA01013212A (es) 2002-06-21
NO20016283D0 (no) 2001-12-20
TWI285118B (en) 2007-08-11
HK1043057A1 (en) 2002-09-06
PL201777B1 (pl) 2009-05-29
CO5190680A1 (es) 2002-08-29
CA2370556C (en) 2009-09-01
SK19112001A3 (sk) 2002-05-09
SK285347B6 (sk) 2006-11-03
DE60011617D1 (de) 2004-07-22
EP1194132B1 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
DE69924283T2 (de) DOSIERUNGSFORM MIT KONTROLLIERTER FREIGABE, DIE ZOLPIDEM ODER EIN SALZ DAVON ENTHäLT
TWI285118B (en) Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
DE69022876T3 (de) Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.
EP1439829B1 (de) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
EP2217210B1 (de) Retardtabletten mit hydromorphon
DE69919713T2 (de) Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium
DD299946A5 (de) Verfahren zur Herstellung von pharmazeutischen Präparaten mit verzögerter Wirkstoffabgabe
US20040258750A1 (en) Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1017392B1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
EP1888075A1 (de) Kombination zur therapie bei benigner prostatahyperplasie
DE3856555T2 (de) Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
DE60308828T2 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung
WO2011006670A1 (de) Trennschichten für pharmazeutische zubereitungen zur verhinderung von wechselwirkungen zwischen arzneistoffen und pharmazeutisch-technologischen hilfsstoffen
DE3850844T2 (de) Orales Präparat von Buspiron und seinen Salzen.
DE19850445A1 (de) Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
DE60312642T2 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
EP2116232B1 (de) Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung
DE10152469A1 (de) 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8363 Opposition against the patent
R082 Change of representative

Ref document number: 1194132

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE